379 related articles for article (PubMed ID: 32418728)
1. Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection.
Micallef J; Soeiro T; Jonville-Béra AP;
Therapie; 2020; 75(4):355-362. PubMed ID: 32418728
[TBL] [Abstract][Full Text] [Related]
2. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality.
Smart L; Fawkes N; Goggin P; Pennick G; Rainsford KD; Charlesworth B; Shah N
Inflammopharmacology; 2020 Oct; 28(5):1141-1152. PubMed ID: 32797326
[TBL] [Abstract][Full Text] [Related]
3. Does Ibuprofen Worsen COVID-19?
Moore N; Carleton B; Blin P; Bosco-Levy P; Droz C
Drug Saf; 2020 Jul; 43(7):611-614. PubMed ID: 32529474
[No Abstract] [Full Text] [Related]
4. ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror.
Kelleni MT
Inflammopharmacology; 2020 Dec; 28(6):1477-1480. PubMed ID: 32920716
[TBL] [Abstract][Full Text] [Related]
5. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?
Brogi S; Calderone V
Br J Clin Pharmacol; 2020 Jun; 86(6):1178-1179. PubMed ID: 32359080
[No Abstract] [Full Text] [Related]
6. NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators?
Capuano A; Scavone C; Racagni G; Scaglione F;
Pharmacol Res; 2020 Jul; 157():104849. PubMed ID: 32360482
[TBL] [Abstract][Full Text] [Related]
7. Is the risk of ibuprofen or other non-steroidal anti-inflammatory drugs increased in COVID-19?
Vosu J; Britton P; Howard-Jones A; Isaacs D; Kesson A; Khatami A; Marais B; Nayda C; Outhred A
J Paediatr Child Health; 2020 Oct; 56(10):1645-1646. PubMed ID: 32862506
[No Abstract] [Full Text] [Related]
8. Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence.
Yousefifard M; Zali A; Zarghi A; Madani Neishaboori A; Hosseini M; Safari S
Int J Clin Pract; 2020 Sep; 74(9):e13557. PubMed ID: 32460369
[TBL] [Abstract][Full Text] [Related]
9. Association of Nonsteroidal Anti-inflammatory Drug Use and Adverse Outcomes Among Patients Hospitalized With Influenza.
Lund LC; Reilev M; Hallas J; Kristensen KB; Thomsen RW; Christiansen CF; Sørensen HT; Johansen NB; Brun NC; Voldstedlund M; Støvring H; Thomsen MK; Christensen S; Pottegård A
JAMA Netw Open; 2020 Jul; 3(7):e2013880. PubMed ID: 32609352
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
Dastan F; Abedini A; Shahabi S; Kiani A; Saffaei A; Zare A
Iran J Allergy Asthma Immunol; 2020 May; 19(S1):10-12. PubMed ID: 32534505
[TBL] [Abstract][Full Text] [Related]
11. Safety of Ibuprofen in Patients With COVID-19: Causal or Confounded?
Sodhi M; Etminan M
Chest; 2020 Jul; 158(1):55-56. PubMed ID: 32243944
[No Abstract] [Full Text] [Related]
12. Targeting Proteases for Treating COVID-19.
Luan B; Huynh T; Cheng X; Lan G; Wang HR
J Proteome Res; 2020 Nov; 19(11):4316-4326. PubMed ID: 33090793
[TBL] [Abstract][Full Text] [Related]
13. ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations.
Snyder EM; Johnson BD
Pharmacogenomics; 2020 Jul; 21(10):695-703. PubMed ID: 32501190
[TBL] [Abstract][Full Text] [Related]
14. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Tseng YH; Yang RC; Lu TS
Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
[TBL] [Abstract][Full Text] [Related]
15. [2019 novel coronavirus, angiotensin converting enzyme 2 and cardiovascular drugs].
Shi HZ; Ma P; Gao FY; Chen GL; Wang YH; Xian XD; Dong ED
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jul; 48(7):532-538. PubMed ID: 32166940
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin Converting Enzyme 2 May Mediate Disease Severity In COVID-19.
Gue YX; Kanji R; Markides V; Gorog DA
Am J Cardiol; 2020 Sep; 130():161-162. PubMed ID: 32636018
[No Abstract] [Full Text] [Related]
17. Is low sodium intake a risk factor for severe and fatal COVID-19 infection?
Post A; Dullaart RPF; Bakker SJL
Eur J Intern Med; 2020 May; 75():109. PubMed ID: 32291196
[No Abstract] [Full Text] [Related]
18. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
19. Covid-19-The real role of NSAIDs in Italy.
de Girolamo L; Peretti GM; Maffulli N; Brini AT
J Orthop Surg Res; 2020 May; 15(1):165. PubMed ID: 32366317
[No Abstract] [Full Text] [Related]
20. COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
Dhawan R; Gundry RL; Brett-Major DM; Mahr C; Thiele GM; Lindsey ML; Anderson DR
J Mol Cell Cardiol; 2020 Jul; 144():12-14. PubMed ID: 32339565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
